In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


This content is currently on FREE ACCESS, enjoy another 18 days of free consultation

In these unprecedented times, the ESC is doing everything it can to support its community: FREE access to all ESC 365 content until 31 July: explore more than 125,000 educational resources.

From 1 August onwards, support our mission by becoming a member.

High-molecular-weight von Willebrand factor multimer ratio for the differentiation between true-severe and pseudo-severe low-flow, low-gradient aortic stenosis

Session Poster Session 5

Speaker Joerg Kellermair

Event : ESC Congress 2018

  • Topic : valvular, myocardial, pericardial, pulmonary, congenital heart disease
  • Sub-topic : Valvular Heart Disease – Diagnostic Methods
  • Session type : Poster Session

Authors : J Kellermair (Linz,AT), H Ott (Munich,DE), D Kiblboeck (Linz,AT), H Blessberger (Linz,AT), J Kammler (Linz,AT), C Reiter (Linz,AT), T Lambert (Linz,AT), M Grund (Linz,AT), C Steinwender (Linz,AT)

Authors:
J. Kellermair1 , H. Ott2 , D. Kiblboeck1 , H. Blessberger1 , J. Kammler1 , C. Reiter1 , T. Lambert1 , M. Grund1 , C. Steinwender1 , 1Kepler University Hospital, Department of Cardiology and Internal Intensive Medicine - Linz - Austria , 2Ludwig-Maximilians University, Department of Hemostasis and Transfusion Medicine - Munich - Germany ,

Citation:
European Heart Journal ( 2018 ) 39 ( Supplement ), 915-916

Background: Subclassification of low-flow, low-gradient (LF/LG) aortic stenosis (AS) into a true-severe (TS) and a pseudo-severe (PS) subform bases on dobutamine stress echocardiography (DSE) and multi-detector computed tomography (MDCT). Uncertainty about stenosis severity frequently persists even after DSE and MDCT, therefore, there is a need for a biomarker-based discrimination to expand the diagnostic portfolio.

Sheer-stress induced degradation of high-molecular-weight (HMW) von Willebrand factor (VWF) multimers is a frequent phenomenon at the site of AS, thus, it might represent a valueable biomarker. The present study analysed the value of HMW VWF multimer ratio for LF/LG AS subcategorization.

Methods: Sixty consecutive patients with diagnosis of LF/LG AS were prospectively recruited and subclassified using DSE and/or MDCT. HMW VWF multimers of all patients were analysed using a densitometric quantification of Western Blot bands and HMW VWF multimer ratio was calculated.

Results: Patients were subclassified into TS LF/LG AS (n=36) and PS LF/LG AS (n=24) using DSE and MDCT. Patients with PS LF/LG AS showed a mean HMW VWF multimer ratio of 1.07±0.09 while in patients with TS LF/LG AS the mean ratio was 0.82±0.28 (p<0.001). HMW VWF ratio presented a ROC-AUC of 0.780 (95% CI: 0.667–0.894; p<0.001) with a calculated sensitivity of 0.47 (95% CI: 0.30–0.65) and a specificity of 1.00 (95% CI: 0.86–1.00) at the optimal cut-off <0.905 for diagnosis of the TS subform.

Conclusion: The present study introduces HMW VWF multimer ratio as a novel biomarker for LF/LG AS subclassification that may be integrated at an early stage of the diagnostic work-up of patients with LF/LG AS.

Comparison of baseline data of patients with TS LF/LG AS and PS LF/LG AS
LF/LG ASp-value
True-severePseudo-severe
Baseline patient characteristics(n=36)(n=24)
  Age (mean years ± SD)81±1079±70.088
  Male Gender (%)29/36 (80.6%)18/24 (75%)0.751
  BMI (mean kg/m2± SD)26±430±6<0.001
Baseline echocardiographic data
  Indexed stroke volume (mean ml/m2 ± SD)28±431±50.450
  Mean aortic gradient (mean mmHg ± SD)29±625±60.002
  AVA (mean cm2± SD)0.73±0.100.84±0.13<0.001
Baseline laboratory characteristics
  proBNP (mean pg/mL ± SD)10951±109907873±137560.039
  HMW VWF multimer ratio (mean ± SD)0.82±0.281.07±0.09<0.001
HMW multimer ratio in PS and TS LF/LG AS


Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are